InvestSMART

Cogstate Limited (ASX:CGS)

ALERT: Price-sensitive ASX Announcement for CGS
Current share price for CGS : $2.880 0.43 (17.55%)+
Announcement
Release
16 Oct 2025 8:29AM
Price at Release
$2.450
Full Release
download
Summary
Cogstate Limited has reported significant growth in demand for its services, with the company executing $21.4 million in sales contracts in 1Q26, marking an 88% increase from the same period last year. The company's expansion into new indications and increased market share are driving this demand, alongside new channel partnerships. Cogstate expects a revenue increase of 18% to 20% for 1H26 and is investing in additional resources for expansion into psychiatry and mood disorders, as well as in data engineering and AI development to enhance its offerings. The company is mindful of potential margin impacts due to these investments.
Key Points
  • Cogstate Limited has experienced a significant increase in demand for its services, driven by the growth in R&D for central nervous system diseases and an expansion of its market share.
  • The company set new records in sales opportunities over the past four quarters, with a 72% increase in the September quarter compared to the previous year.
  • In 1Q26, Cogstate executed $21.4 million in sales contracts, marking the second highest quarterly result in its history, and an 88% increase year-over-year.
  • The company is expanding into new indications and increasing its customer base, while monitoring win rates and assessing the impact of new channel partnerships.
  • Financial outlook for 1H26 is positive, with an expected revenue increase of 18% to 20% from the previous corresponding period.
  • Cogstate is investing in growth, including additional resources for expansion into psychiatry and mood disorders, as well as data engineering and AI tool development.
  • The company is cautious about potential margin impacts due to increased investments, estimating a possible decrease of 0-3 percentage points.
  • Cogstate is focused on providing rapid, reliable cognitive tests and eCOA solutions to improve clinical trial efficiency and accuracy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.